Biomarkers expression in benign breast diseases and risk of subsequent breast cancer : a case-control study

Biomarkers expression in benign breast diseases and risk of subsequent breast cancer : a case-control study

Women with benign breast diseases (BBD) have a high risk of breast cancer. However, no biomarkers have been clearly established to predict cancer in these women. Our aim was to explore whether estrogen receptor (ER), progesterone receptor (PR), and Ki67 expression stratify risk of breast cancer in s...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Posso, Margarita, Corominas, Josep, Serrano, Laia, Román, Marta, Torá-Rocamora, Isabel, Domingo, Laia, Romero, Anabel, Quintana Ruiz, Maria Jesús, Vernet-Tomas, Maria, Baré i Mañas, Marisa, Vidal, Carmen, Sánchez, Mar, Saladié, Francina, Natal, Carmen, Ferrer, Joan, Servitja, Sonia, Sala, Maria, Castells, Xavier, Burón, A, Rodríguez-Arana, A, Romero, A, Vernet, M, Andreu, Xavier, Milà, N, López Vilaró, Laura, Fernández-Somoano, A, Galceran, Jaume, Espinàs, J.A, Universitat Autònoma de Barcelona
Format: Artikel
Sprache:eng
Schlagworte:
Benign breast disease
Biomarkers
Breast cancer
Early detection
Screening
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Women with benign breast diseases (BBD) have a high risk of breast cancer. However, no biomarkers have been clearly established to predict cancer in these women. Our aim was to explore whether estrogen receptor (ER), progesterone receptor (PR), and Ki67 expression stratify risk of breast cancer in screened women with BBD. We conducted a nested case-control study. Women with breast cancer and prior BBDs (86 cases) were matched to women with prior BBDs who were free from breast cancer (172 controls). The matching factors were age at BBD diagnosis, type of BBD, and follow-up time since BBD diagnosis. ER, PR, and Ki67 expression were obtained from BBDs' specimens. Conditional logistic regression was used to estimate odds ratios (ORs), and 95% confidence intervals (CIs) of breast cancer risk according to ER, PR, and Ki67 expression. Women with